Elijah Darnell

Dr. Darnell is an expert in the treatment of B- and T-cell lymphomas and chronic lymphocytic leukemia (CLL). He has a special interest in clinical investigation of novel agents for the treatment of lymphoma including CAR T-cell therapy, bispecific antibodies, targeted therapies, and other immune therapies. He leads research in the development of novel CAR T-cell therapies and is an investigator for efforts to use combinatorial therapy with CAR T-cells to overcome resistant lymphomas. He is additionally interested in the immunologic consequences of CLL and leads an effort to develop a functional characterization of immunity to guide infection prevention in patients with CLL.